ALLOSTERIC TRANS-SPLICING GROUP I RIBOZYME WHOSE ACTIVITY OF TARGET-SPECIFIC RNA REPLACEMENT IS CONTROLLED BY THEOPHYLLINE
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jan 6, 2011
app pub date -
Dec 16, 2008
filing date -
Mar 27, 2008
priority date (Note) -
Abandoned
status (Latency Note)
Importance
|
US Family Size
|
Non-US Coverage
|
Abstract
Provided is an allosteric trans-splicing group I ribozyme whose target-specific RNA replacement activity is controlled by theophylline, wherein the hTERT-targeting trans-splicing ribozyme recognizes mRNA of human telomerase reverse transcriptase (hTERT) as a cancer-specific RNA transcript to bind a theophylline aptamer to an hTERT target trans-splicing ribozyme via a communication module, the hTERT target trans-splicing ribozyme having a verified trans-splicing ability. The allosteric trans-splicing group I ribozyme may be useful to selectively diagnose only cancer cells that express target hTERT RNA, or induce their apoptosis since the activity of the allosteric trans-splicing group I ribozyme is dependently controlled by theophylline to correct target hTERT RNA by the trans-splicing reaction.
First Claim
Other Claims data not available
Family
| Country | kind | publication No. | Filing Date |
|---|---|---|---|
| KR | B1 | KR100958293 | Mar 27, 2008 |
| CN | B | CN101688231 | Dec 16, 2008 |
| JP | B2 | JP4908631 | Dec 16, 2008 |
| WO | A1 | WO2009119965 | Dec 16, 2008 |
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
- 3 Citation Count
- A61K Class
- 10.68 % this patent is cited more than
- 14 Age